Radioligand Therapy Continues to Show Promise for Metastatic CRPC

(MedPage Today) -- Radioligand therapy (RLT) with actinium-225 targeting prostate-specific membrane antigen (225Ac-PSMA) had a "substantial antitumor effect" in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC), a large...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news